Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports

The manufacturer of the testosterone injection, Delatestryl, is facing a class action lawsuit alleging that the company failed to warn about the risk of cardiovascular events, including blood clot, stroke, heart attack, and death. There have been global, mounting concerns about the risks of testosterone replacement drugs after regulators began investigating the issue; the safety reviews were prompted by two studies showing a higher risk of cardiovascular issues in men who use testosterone products.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
“Testosterone lawsuits have been on the rise after the FDA began investigating the purported cardiovascular risks associated with these drugs,” said Gary Falkowitz, Managing Attorney at Parker Waichman LLP.

Port Washington, New York (PRWEB) July 29, 2014

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, reports that a class action lawsuit has been filed by plaintiffs in Canada who allege that they were never warned about the increased risk of cardiovascular events with the low testosterone injection Delatestryl (Court File No. 3704CP/14). The case was filed on July 22, 2014 in the Ontario Superior Court of Justice.

“Testosterone lawsuits have been on the rise after the FDA began investigating the purported cardiovascular risks associated with these drugs,” said Gary Falkowitz, Managing Attorney at Parker Waichman LLP. “Our firm has been following these reports closely, and anticipates that more lawsuits are on the way.” Parker Waichman LLP offers free legal advice for men who suffered cardiovascular events such as blood clot, stroke, and heart attack allegedly related to the use of testosterone medications.

A multidistrict litigation involving over 150 testosterone lawsuits is also pending in the U.S. District Court for the Northern District of Illinois. The case is In Re: Testosterone Replacement Therapy Product Liability Litigation (MDL No. 2545).

Testosterone products, used to treat so-called “Low T,” have been linked to serious cardiovascular problems such as pulmonary embolism, deep vein thrombosis (DVT), stroke, heart attack, and death. The U.S. Food and Drug Administration(FDA) began investigating the cardiovascular risks associated with testosterone products in late January; the agency reminded consumers that testosterone products are only approved for men who do not produce enough of the hormone due to specific medical conditions. Testosterone replacement therapy is not approved for Low T or other non-medical conditions.

Testosterone safety reviews were also launched by the European Medicines Agency(EMA) and Health Canada, notes Parker Waichman LLP. Recently, warned the public that there is a growing body of evidence suggesting that testosterone therapy may increase the risk of cardiovascular events in men.

The reviews were prompted by two research studies linking testosterone products to a higher risk of blood clot, stroke and heart attack. One study, published in last November in the Journal of the American Medical Association, found that older men were more likely to suffer cardiac death if they took testosterone. Older men and younger men with pre-existing heart problems were more likely to suffer a heart attack, according to another study published January in the journal, PloS.

If you or someone you know has taken a Low T medication, you may have valuable legal rights. To discuss your case with one of our lawyers, please view our Testosterone lawsuit website or call 1-800-LAW-INFO (1-800-529-4636).


Contact

Follow us on: Contact's Google Plus